{"version":"1.0","provider_name":"All About Cardiovascular System and Disorders","provider_url":"https:\/\/johnsonfrancis.org\/professional","author_name":"Johnson Francis","author_url":"https:\/\/johnsonfrancis.org\/professional\/author\/jf\/","title":"CANTOS Trial of Canakinumab - All About Cardiovascular System and Disorders","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"iH9lam0gc5\"><a href=\"https:\/\/johnsonfrancis.org\/professional\/cantos-trial-of-canakinumab\/\">CANTOS Trial of Canakinumab<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/johnsonfrancis.org\/professional\/cantos-trial-of-canakinumab\/embed\/#?secret=iH9lam0gc5\" width=\"600\" height=\"338\" title=\"&#8220;CANTOS Trial of Canakinumab&#8221; &#8212; All About Cardiovascular System and Disorders\" data-secret=\"iH9lam0gc5\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/johnsonfrancis.org\/professional\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","thumbnail_url":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2025\/07\/CANTOS-Trial-of-Canakinumab.jpg","thumbnail_width":1200,"thumbnail_height":680,"description":"Canakinumab is a humanized monoclonal antibody targeting interleukin-1\u03b2. Experimental and clinical information had suggested that reducing inflammation even without affecting lipid levels may reduce the risk of cardiovascular disease. This novel concept was tested in the CANTOS trial involving over ten thousand patients with prior myocardial infarction and elevated high sensitivity C-reactive protein (hsCRP). Three [&hellip;]"}